FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200510645> ?p ?o ?g. }

• W4200510645 endingPage "S721" @default.
• W4200510645 startingPage "S720" @default.
• W4200510645 abstract "Abstract Background Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination with in vitro activity against Enterobacterales (Ent) and Pseudomonas aeruginosa (Psa) carrying Class A, C and some Class D β-lactamases. We examined the in vitro activity of CAZ-AVI and comparators against presumed community-acquired (CA; cultured &lt; 48 h after hospital admission) and hospital-acquired (HA; cultured ≥48 h post-admission) isolates collected from pediatric patients as part of the ATLAS surveillance program. Methods 6654 non-duplicate isolates were collected in 52 countries in Europe (n=3423), Latin America (n=1323), Middle East/Africa (n=1177), and Asia/Pacific (excluding China; n=731) from patients (newborn to 17 y) with lower respiratory tract (LRTI; n=1687), urinary tract (UTI; n=1631), bloodstream (BSI; n=1149), skin and soft tissue (SSTI; n=1122), and intra-abdominal (IAI; n=981) infections. Susceptibility testing was performed by CLSI broth microdilution and values were interpreted using CLSI 2021 breakpoints. CAZ-AVI was tested at a fixed concentration of 4 µg/mL AVI. Isolates with CAZ or aztreonam MICs ≥2 µg/mL (Escherichia coli, Klebsiella spp., Proteus mirabilis) or meropenem MICs ≥2 µg/mL (all Ent species) or ≥4 µg/mL (Psa) were screened for β-lactamase genes. Results The in vitro activity of CAZ-AVI exceeded that of meropenem and other tested β-lactams against Ent (97.8% susceptible (S)) and Psa (92.1% S) collected globally from pediatric patients (Table). Percentages of susceptibility to CAZ-AVI ranged from 95.4-99.2% among CA Ent from different infection types and were reduced 0.6-1.3% among HA isolates from LRTI, UTI, SSTI, and IAI. Susceptibility to CAZ-AVI was also similar (92.6-95.8% S) among CA Psa from different infection types and was reduced 1.2-7.0% among HA isolates. Larger differences in susceptibility were typically seen for the tested comparator β-lactams. For Ent, the lowest percentages of susceptibility to the tested β-lactams were observed among isolates from BSI, while the pattern was less clear for Psa. Results Table Conclusion CAZ-AVI could provide a valuable therapeutic option for treatment of CA and HA infections caused by Ent and Psa in pediatric patients. Disclosures Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Gregory Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
• W4200510645 created "2021-12-31" @default.
• W4200510645 creator A5017159626 @default.
• W4200510645 creator A5020992600 @default.
• W4200510645 creator A5038009031 @default.
• W4200510645 creator A5066677972 @default.
• W4200510645 date "2021-11-01" @default.
• W4200510645 modified "2023-10-16" @default.
• W4200510645 title "1264. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Pediatric Patients, ATLAS Surveillance Program 2016-2019" @default.
• W4200510645 doi "https://doi.org/10.1093/ofid/ofab466.1456" @default.
• W4200510645 hasPublicationYear "2021" @default.
• W4200510645 type Work @default.
• W4200510645 citedByCount "0" @default.
• W4200510645 crossrefType "journal-article" @default.
• W4200510645 hasAuthorship W4200510645A5017159626 @default.
• W4200510645 hasAuthorship W4200510645A5020992600 @default.
• W4200510645 hasAuthorship W4200510645A5038009031 @default.
• W4200510645 hasAuthorship W4200510645A5066677972 @default.
• W4200510645 hasBestOaLocation W42005106451 @default.
• W4200510645 hasConcept C176947019 @default.
• W4200510645 hasConcept C2775933652 @default.
• W4200510645 hasConcept C2776968632 @default.
• W4200510645 hasConcept C2777637488 @default.
• W4200510645 hasConcept C2779375183 @default.
• W4200510645 hasConcept C2780416669 @default.
• W4200510645 hasConcept C2780950330 @default.
• W4200510645 hasConcept C501593827 @default.
• W4200510645 hasConcept C523546767 @default.
• W4200510645 hasConcept C54355233 @default.
• W4200510645 hasConcept C71924100 @default.
• W4200510645 hasConcept C86803240 @default.
• W4200510645 hasConcept C89423630 @default.
• W4200510645 hasConcept C94665300 @default.
• W4200510645 hasConceptScore W4200510645C176947019 @default.
• W4200510645 hasConceptScore W4200510645C2775933652 @default.
• W4200510645 hasConceptScore W4200510645C2776968632 @default.
• W4200510645 hasConceptScore W4200510645C2777637488 @default.
• W4200510645 hasConceptScore W4200510645C2779375183 @default.
• W4200510645 hasConceptScore W4200510645C2780416669 @default.
• W4200510645 hasConceptScore W4200510645C2780950330 @default.
• W4200510645 hasConceptScore W4200510645C501593827 @default.
• W4200510645 hasConceptScore W4200510645C523546767 @default.
• W4200510645 hasConceptScore W4200510645C54355233 @default.
• W4200510645 hasConceptScore W4200510645C71924100 @default.
• W4200510645 hasConceptScore W4200510645C86803240 @default.
• W4200510645 hasConceptScore W4200510645C89423630 @default.
• W4200510645 hasConceptScore W4200510645C94665300 @default.
• W4200510645 hasIssue "Supplement_1" @default.
• W4200510645 hasLocation W42005106451 @default.
• W4200510645 hasLocation W42005106452 @default.
• W4200510645 hasOpenAccess W4200510645 @default.
• W4200510645 hasPrimaryLocation W42005106451 @default.
• W4200510645 hasRelatedWork W2141204124 @default.
• W4200510645 hasRelatedWork W2261913017 @default.
• W4200510645 hasRelatedWork W2895024254 @default.
• W4200510645 hasRelatedWork W2901057130 @default.
• W4200510645 hasRelatedWork W3119311612 @default.
• W4200510645 hasRelatedWork W3196668908 @default.
• W4200510645 hasRelatedWork W4200472874 @default.
• W4200510645 hasRelatedWork W4311733020 @default.
• W4200510645 hasRelatedWork W4311738242 @default.
• W4200510645 hasRelatedWork W4367843616 @default.
• W4200510645 hasVolume "8" @default.
• W4200510645 isParatext "false" @default.
• W4200510645 isRetracted "false" @default.
• W4200510645 workType "article" @default.